PATENT CLAIM ANALYSIS

Application Number: 15950042
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-12
Patent Classification: ["424", "093730"]

Abstract:
The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.

Claim (Index 114):
A method of treating a patient having a tumor comprising (i) administering to the patient a single dose of cyclophosphamide from about 900 mg/m 2  to about 1000 mg/m 2  and one or more dose of fludarabine of about 25 mg/m 2 /day, about 30 mg/m 2 /day, about 35 mg/m 2 /day, about 40 mg/m 2 /day, about 45 mg/m 2 /day, or about 50 mg/m 2 /day, and (ii) administering to the patient a therapeutically effective amount of from about 1\u00d710 6  to about 5\u00d710 6  engineered CAR T cells/kg.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 91.0
- Lexical Diversity: 1.6
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15649369', '15167977', '14680860', '14996953', '14918451']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7626137707172118
- 35 USC 102 Novelty (BERT): 0.6291822478898269
- Combined Prediction Score: 0.7492706184344733
- Mean Citation Score: 486.130018
- Max Citation Score: 702.39386
- Similarity Product: 521.6046049949147

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test